Highlights LianBio

Equities

LIANY

US53000N1081

Market Closed - OTC Markets Other stock markets 15:59:59 2024-07-05 EDT			5-day change	1st Jan Change
0.31 ^USD	+1.64%		-1.59%	-93.06%

05-10	China's Zeekr prices US IPO at top of range to raise $441 million	RE
05-07	Geely's EV Unit Zeekr Targets Up to $367.5 Million From NYSE IPO	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

China's Zeekr prices US IPO at top of range to raise $441 million	05-10	RE
Geely's EV Unit Zeekr Targets Up to $367.5 Million From NYSE IPO	05-07	MT
LianBio to Start Winding Down Operations; Complete Dissolution Expected in 2027	02-13	MT
Nanobiotix: transfer of NBTXR3 rights in Asia	12-27	CF
Nanobiotix Partner Transfers Asian Commercialization Rights for Oncology Therapy to Johnson & Johnson Unit	12-27	MT
LianBio Enters into Agreement with Janssen Pharmaceutica to Assign its Rights for NBTXR3 in China and Other Asian Markets	12-26	CI
LianBio Rejects Concentra Biosciences' Unsolicited Acquisition Proposal	12-07	MT
Concentra Biosciences, LLC cancelled the acquisition of LianBio from Tang Capital Partners, LP, managed by Tang Capital Management, LLC and others.	12-05	CI
LianBio Receives Unsolicited Proposal From Concentra Biosciences to be Acquired for $4.30 Per Share Plus Contingent Value Right	12-01	MT
Concentra Biosciences, LLC submit non-binding proposal to acquire LianBio.	11-29	CI
LianBio Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
LianBio Announces Topline Results from Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis	23-10-30	CI
LianBio Announces Presentation of Data from Phase 2a Study of Infigratinib in Patients with Gastric Cancer at ESMO Congress 2023	23-10-25	CI
LianBio Signs Agreement With Bristol-Myers Squibb on Exclusive Rights to Mavacamten in China, Other Asian Markets	23-10-24	MT
LianBio Enters into Agreement with Bristol Myers Squibb for Mavacamten in China and Other Asian Markets	23-10-24	CI
LianBio Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
LianBio Announces First Patient Treated in Phase 1 Trial of SHP2 Inhibitor BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations	23-08-03	CI
LianBio, Tarsus Pharmaceuticals Get US FDA Approval For Xdemvy in Treating Eye Disease Demodex Blepharitis	23-07-26	MT
LianBio Announces Clinical Supply Agreement with AstraZeneca in China to Evaluate BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations	23-07-12	CI
LianBio Says Its Camzyos Drug Receives Marketing Approval From Singapore Health Sciences Authority	23-06-26	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights LianBio

Equities

LIANY

US53000N1081

Highlights

Filters